A Healthcare Technology Company

Shaping the future of non-invasive diagnosis with artificial intelligence.

Uniquely Position among Non-invasive technologies

A single blood draw diagnostic powered by Artificial intelligence
on broadly available biomarkers that provides equivalence to a biopsy.

Fibronostics patent technology

Patent Technology

CPT Code: 0166U

Fibronostics FDA – De Novo 510K

De Novo 510K

(in Progress)

Fibronostics CE (Conformité Européenne) mark

CE mark

(Conformité Européenne)

Fibronostics CLIA Certified

CLIA Certified

Fibronostics Cloud Platform

Artificial Technology Cloud Platform

LIVERFASt™ has now been granted a CPT Code.

The American Medical Association (AMA) and The Centers for Medicare & Medicaid Services (CMS) awarded LIVERFASt™ a CPT Code with the highest reimbursement fee in its category!

70,000+ Patients Screened
50+ Network Health System
30+ Laboratories
900+ Medical centers & Pharmacies

Complete Liver Diagnosis

LIVERFASt™ – from Early Stage to Late Stage
for NAFLD, NASH, Cirrhosis, HCV, HBV & Hepatocellular Carcinoma.

Fibronostics Diagnosis


Non-invasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.

Fibronostics Screening


Risk stratification among large patient populations allows for better management leading to cost reductions.

Fibronostics Monitoring


Regular surveillance with easily repeatable non-invasive diagnostics enables optimized disease management.

Non-invasive solutions for diagnosis, screening and monitoring.


Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors

Learn more